Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded by StockNews.com to “Sell” Rating

StockNews.com upgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) to a sell rating in a report issued on Tuesday morning.

Several other research analysts have also recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, September 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, September 26th. Chardan Capital reissued a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, July 17th. Piper Sandler reaffirmed an “overweight” rating and set a $62.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, October 8th. Finally, B. Riley reissued a “buy” rating and issued a $55.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $45.33.

Arrowhead Pharmaceuticals Stock Down 1.0 %

ARWR opened at $21.41 on Tuesday. The company’s 50-day moving average price is $20.19 and its 200 day moving average price is $23.45. The firm has a market cap of $2.66 billion, a price-to-earnings ratio of -4.58 and a beta of 0.93. Arrowhead Pharmaceuticals has a fifty-two week low of $17.05 and a fifty-two week high of $39.83.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Swiss National Bank boosted its stake in Arrowhead Pharmaceuticals by 21.2% in the 1st quarter. Swiss National Bank now owns 243,300 shares of the biotechnology company’s stock worth $6,958,000 after purchasing an additional 42,600 shares during the period. Headlands Technologies LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 7,696.8% during the first quarter. Headlands Technologies LLC now owns 2,417 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 2,386 shares in the last quarter. ProShare Advisors LLC raised its position in Arrowhead Pharmaceuticals by 21.7% during the first quarter. ProShare Advisors LLC now owns 35,592 shares of the biotechnology company’s stock valued at $1,018,000 after buying an additional 6,341 shares during the period. State Board of Administration of Florida Retirement System lifted its stake in Arrowhead Pharmaceuticals by 14.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 33,353 shares of the biotechnology company’s stock worth $954,000 after acquiring an additional 4,140 shares in the last quarter. Finally, Gratus Wealth Advisors LLC acquired a new stake in Arrowhead Pharmaceuticals during the 1st quarter worth about $350,000. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.